66. IgA nephropathy
199 clinical trials,   214 drugs   (DrugBank: 57 drugs),   32 drug target genes,   128 drug target pathways
Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02571842 (ClinicalTrials.gov) | January 2012 | 6/10/2015 | Rituximab in Recurrent IgA Nephropathy | A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology | Recurrent IgA Nephropathy | Drug: Intravenous Rituximab;Drug: ACEI/ARB and corticosteroids | Chulalongkorn University | NULL | Recruiting | 18 Years | 70 Years | Both | 30 | Phase 4 | Thailand |
2 | NCT00498368 (ClinicalTrials.gov) | February 2009 | 9/7/2007 | Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy | A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy | IgA Nephropathy | Drug: Intravenous Rituximab;Drug: ACE/ARB;Dietary Supplement: Omega-3 Fatty Acid Fish Oil Supplement | Mayo Clinic | Ohio State University;Stanford University;University of North Carolina, Chapel Hill;Columbia University;Genentech, Inc.;Biogen | Completed | 18 Years | 70 Years | All | 34 | Phase 4 | United States |